HW
AQST icon

Hancock Whitney’s Aquestive Therapeutics AQST Stock Holding History

Hancock Whitney’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-18,893
Closed -$92K – 793
2020
Q3 		$92K Sell
18,893
-4,400
-19% -$28.8K ﹤0.01% 762
2020
Q2 		$113K Buy
+23,293
New +$107K ﹤0.01% 752

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
BCL
Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Hancock Whitney's AQST Position: Q4 2020 in Review

Hancock Whitney sold out of Aquestive Therapeutics (AQST) in Q4 2020, closing a stake of 18,893 shares — an estimated $92K sold.

Hancock Whitney first reported a position in AQST in Q2 2020 and held it in 2 quarters. The position peaked at $113K in Q2 2020. 65 funds tracked by Wall St. Rank hold AQST as of Q4 2020.

  • Hancock Whitney reported no remaining Aquestive Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Hancock Whitney sold 18,893 Aquestive Therapeutics shares in Q4 2020, an estimated $92K.
  • Hancock Whitney first reported a position in Aquestive Therapeutics in Q2 2020 and held it in 2 quarters.
  • Hancock Whitney's Aquestive Therapeutics position peaked at $113K in Q2 2020.
  • 65 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q4 2020.

Based on Hancock Whitney's 13F filing for Q4 2020, filed 9 Feb 2021.